

Tuesday 21st November 2017
BACR Development of Cancer Medicines Conference
Royal Society of Medicine, 1 Wimpole Street

Precision medicine and cancer models: developing strategies to enhance clinical response

The use of preclinical and clinical information to inform patient selection for novel cancer therapies is key, with the development and use of models to interrogate target dependencies based on molecular pathology being well-established. Recent studies also suggest that it may be valuable to integrate additional information into patient selection hypotheses, including considerations of tumor metabolism, the type and extent of immunological infiltrate in a tumour, or the acquisition of a mesenchymal phenotype. This one-day conference involves leading investigators working at the translational interface in oncology to better define disease subtypes and guide precision medicine decisions.

An interactive poster/poster discussion session will also be held relevant to anyone involved in modelling cancer disease and assessing therapeutic responses.

09.00 Coffee/Tea/Registration

10.00 Welcome and Introduction: Steve Wedge

Session 1

Chair: Val Brunton (Edinburgh Cancer Research Centre)

10.10 JP Medema (Academic Medical Centre, Netherlands) – Use of models and clinical material to inform subtyping of colorectal cancer

10.45 Jerome Galon (Cordeliers Research Center, Paris) – Classifying tumours for treatment decisions based on immunogenic subtype

11.20 Nicholas Turner (The Institute of Cancer Research, London) – Biomarker strategies to improve the personalisation of breast cancer treatment

11.55 - 13.15 (Poster viewing and Lunch)

Session 2 Poster Discussion session (10 minute presentations and 5-minute discussion)

Chair: Owen Sansom (CRUK Beatson Institute, Glasgow)

- 13.15 Selected Poster Discussion 1
- 13.30 Selected Poster Discussion 2
- 13.45 Selected Poster Discussion 3
- 14.00 Selected Poster Discussion 4
- 14.15 Selected Poster Discussion 5
- 14.30 Selected Poster Discussion 6

14.45 -15.15 Refreshment break

Session 3

Chair: Steve Wedge (Northern Institute for Cancer Research, Newcastle University)

- 15.15 **Lars Zender (University Hospital Tübingen, Germany) – Experimental strategies to reveal therapeutic targets in liver cancer**
- 15.50 **Cathrin Brisken (ISREC - Swiss Institute for Experimental Cancer Research, Switzerland) – Modelling the microenvironment in ER α -positive breast cancer**
- 16.25 **Andrew Biankin (CRUK Beatson Institute, Glasgow) – Modelling pancreatic adenocarcinoma to reveal insights into disease biology and potential therapeutic approaches**

17.00 Close